Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 27 Parkinson's papers of 1,081 | 0.56 |
| pathways Reactome | 3 pathways; mostly iron and oxidative stress | 0.80 |
No case: the score is under the bar. Receipt 3859
Sealed predictions
- ATP7A in dopamine neurons, braak-0.20 (p 0.613) → +0.88 (p 0.002)receipt 3865
Swarm cases
receipt 3865: ATP7A in dopamine neurons, braak
- power
- full sample +0.25 (p 0.315, n 18), 95% CI -0.24 to +0.64. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.30 (p 0.228, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.29 (p 0.243, n 18). could be the mix.
- skeptic
- leave-one-out range +0.18 to +0.39, sign flips 0; without severely affected donors +0.25 (p 0.315, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.62 (p 0.0057, n 18) vs +0.25 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ATP7A in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ATP7A · oligodendrocytes · braak: substantia nigra, an independent cohort: not measured
Receipts
loading the receipts